Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients’ quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.
Telix’s $397M convertible bond offering; Scynexis records a $10M milestone
Plus, news about Windtree Therapeutics, MEI Pharma and ViiV: Telix raises $397M in convertible bond offering: The radiopharma biotech plans to use the funds to